ADAM trial: A multicenter, randomized, double-blinded, placebo-controlled, phase 3 trial of adjuvant avelumab (anti-PD-L1 antibody) in merkel cell carcinoma patients with clinically detected lymph node metastases; NCT03271372

被引：5

作者：

Bhatia, Shailender

Brohl, Andrew Scott

Brownell, Isaac

Chandra, Sunandana

Dakhil, Sumia

Ernstoff, Marc S.

Fecher, Leslie Anne

Gooley, Ted

Hanna, Glenn J.

Hibbert, Reina

Kelly, Ciara Marie

Kiriluk, Samantha M.

Nghiem, Paul

Vivian Nguyen

Pelz, Nichole

Poisson, Aubrey A.

Price, Katharine Andress Rowe

Sondak, Vernon K.

Thompson, John A.

Tykodi, Scott S.

机构：

[1] Univ Washington, Fred Hutchinson Canc Ctr, Seattle, WA USA

[2] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[3] NCI, Bethesda, MD 20892 USA

[4] Northwest Univ, Chicago, IL USA

[5] Univ Washington, Seattle, WA 98195 USA

[6] Roswell Park Comprehens Canc Ctr, Buffalo, NY USA

[7] Univ Michigan, Ann Arbor, MI 48109 USA

[8] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA

[9] Dana Farber Canc Inst, Boston, MA 02115 USA

[10] Seattle Canc Care Alliance, Seattle, WA USA

[11] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA

[12] Mayo Clin, Rochester, MN USA

来源：

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.TPS9605

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS9605

引用

页数：2